Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.88 - $19.30
Previous CloseN/A
Volume7.67K
Average Volume (3M)344.89K
Market Cap
$52.96M
Enterprise Value$22.04M
Total Cash (Recent Filing)$49.42M
Total Debt (Recent Filing)$18.66M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jun 12, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding32,692,387
10 Day Avg. Volume231,992
30 Day Avg. Volume344,893
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$13.25Price Target Upside722.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
PepGen Inc. News
PremiumCompany Announcements
PepGen Inc. Expands Board with New Appointments
PremiumCompany Announcements
PepGen Inc. Reports Positive Trial Results and Financials
---
Bulls Say, Bears Say
Bulls Say
Efficacy PotentialSplicing data hints of PGN-EDODM1’s potential to be best-in-class.
Safety ProfileThe safety appears to be cleaner than what has been seen in Duchenne muscular dystrophy, with no adverse effects related to electrolytes or renal function.
Splicing CorrectionThe initial data from the FREEDOM-DM1 trial highlighted a dose-dependent robust increase in the splicing correction at 28 days just after one dose.
Bears Say
Clinical HoldsWe continue to view the DMD clinical holds as a key stock overhang supporting our current Underperform thesis.
Competitive LandscapeThere are a number of competitors further ahead in development (RNA, DYN, etc.).
Functional Outcome DataThe company also presented early functional outcome data that did not demonstrate a meaningful difference from placebo.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $19.30 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $52.96M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Jun 12, 2025 which is in 48 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Feb 24, 2025. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.134.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.72.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 32,692,387 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went up 67.153%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
---
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.25 (722.98% Upside)
$13.25 (722.98% Upside)
Blogger Sentiment
Bullish
PEPG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 580.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.77%
12-Months-Change
Fundamentals
Return on Equity
-79.26%
Trailing 12-Months
Asset Growth
5.47%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
---
PEPG Stock 12 Month Forecast
Average Price Target
$13.25
▲(722.98% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Dyadic International
―
X4 Pharmaceuticals
―
Xilio Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Best Analysts Covering PEPG
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-30.91%
reiterated a buy rating 2 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -30.91% per trade.
---